Patents by Inventor Yves Ducharme

Yves Ducharme has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazolyl derivatives as Syk inhibitors
    Patent number: 9586931
    Abstract: Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: March 7, 2017
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Michelle R. Machacek, Eric T. Romeo, Solomon D. Kattar, Matthew Christopher, Michael D. Altman, Alan B. Northrup, John Michael Ellis, Brendan O'Boyle, Anthony Donofrio, Jonathan Grimm, Michael H. Reutershan, Kaleen Konrad Childers, Ryan D. Otte, Brandon Cash, Yves Ducharme, Andrew M. Haidle, Kerrie Spencer, Dilrukshi Vitharana, Lingyun Wu, Li Zhang, Peng Zhang, Christian Beaulieu, Daniel Guay
  • Pyrazolyl derivatives as Syk inhibitors
    Patent number: 9242984
    Abstract: The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: January 26, 2016
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Michelle R. Machacek, Michael D. Altman, Eric T. Romeo, Dilrukshi Vitharana, Brandon Cash, Tony Siu, Hua Zhou, Matthew Christopher, Solomon D. Kattar, Andrew M. Haidle, Kaleen Konrad Childers, Matthew L. Maddess, Michael H. Reutershan, Yves Ducharme, David J. Guerin, Kerrie Spencer, Christian Beaulieu, Vouy Linh Truong, Daniel Guay, Alan B. Northrup, Brandon M. Taoka, Jongwon Lim, Christian Fischer, John W. Butcher, Ryan D. Otte, Binyuan Sun, John Michael Ellis
  • TRIAZOLYL DERIVATIVES AS SYK INHIBITORS
    Publication number: 20150239866
    Abstract: Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Application
    Filed: September 24, 2013
    Publication date: August 27, 2015
    Applicants: MERCK CANADA INC., MERCK SHARP & DOHME CORP.
    Inventors: Michelle R. MACHACEK, Eric T. ROMEO, Solomon D. KATTAR, Matthew CHRISTOPHER, Michael D. ALTMAN, Alan B. NORTHRUP, John Michael ELLIS, Brendan O BOYLE, Anthony DONOFRIO, Jonathan GRIMM, Michael H. REUTERSHAN, Kaleen Konrad CHILDERS, Ryan D. OTTE, Brandon CASH, Yves DUCHARME, Andrew M. HAIDLE, Kerrie SPENCER, Dilrukshi VITHARANA, Lingyun WU, Li ZHANG, Peng ZHANG, Christian BEAULIEU, Daniel GUAY
  • PYRAZOLYL DERIVATIVES AS SYK INHIBITORS
    Publication number: 20150191461
    Abstract: The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Application
    Filed: June 18, 2013
    Publication date: July 9, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, Michael D. Altman, Eric T. Romeo, Dilrukshi Vitharana, Brandon Cash, Tony Siu, Matthew Christopher, Solomon D. Kattar, Andrew M. Haidle, Kaleen Konrad Childers, Matthew L. Maddess, Michael H. Reutershan, Yves Ducharme, David J. Guerin, Kerrie Spencer, Christian Beaulieu, Vouy Linh Truong, Daniel Guay, Alan B. Northrup, Brandon M. Taoka, Jongwon Lim, Christian Fischer, John W. Butcher, Ryan D. Otte, Binyuan Sun, John Michael Ellis
  • Pharmaceutical phenylquinoline and chromen-2-one triazole compounds
    Patent number: 7960409
    Abstract: The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: June 14, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Erich L. Grimm, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Yves Gareau
  • 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Patent number: 7943649
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: May 17, 2011
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
    Publication number: 20090286772
    Abstract: The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: February 22, 2007
    Publication date: November 19, 2009
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Pierre Hamel
  • Phenanthrene derivatives as MPGES-1 inhibitors
    Publication number: 20090209571
    Abstract: The invention encompasses novel compounds of Formula or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: May 15, 2007
    Publication date: August 20, 2009
    Inventors: Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Andre Giroux, Evelyn Martins, Pierre Hamel
  • 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Publication number: 20090075998
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: October 24, 2008
    Publication date: March 19, 2009
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis
    Publication number: 20090054483
    Abstract: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 26, 2009
    Inventors: Yves Ducharme, Tom Yao-Hsiang Wu, Richard Frenette
  • 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Patent number: 7442716
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: October 28, 2008
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • Novel pharmaceutical compounds
    Publication number: 20080188521
    Abstract: The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: February 1, 2008
    Publication date: August 7, 2008
    Inventors: Erich L. Grimm, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Yves Gareau
  • 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Publication number: 20070208017
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: November 23, 2005
    Publication date: September 6, 2007
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • Use of phosphodiesterase-4 inhibitors as enhancers of cognition
    Publication number: 20060040981
    Abstract: The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and effective amount of a phosphodiesterase-4 inhibitor.
    Type: Application
    Filed: November 19, 2003
    Publication date: February 23, 2006
    Inventors: Daniel Dube, Michel Gallant, Patrick Lacombe, Yves Girard, Dwight Macdonald, Richard Friesen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte, Annette Robichaud, Anthony Mastracchio, Helene Perrier
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6841564
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6639077
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: October 28, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Bernard Cote, Evelyn Martins, Richard Frenette, Rick Friesen, Yves Ducharme
  • Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
    Patent number: 6486194
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020173661
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 20, 2002
    Publication date: November 21, 2002
    Applicant: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020156105
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 29, 2002
    Publication date: October 24, 2002
    Inventors: Bernard Cote, Evelyn Martins, Richard Frenette, Rick Friesen, Yves Ducharme
  • Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
    Patent number: 6448274
    Abstract: A PDE4 inhibiting compound is represented by
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: September 10, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Friesen, Yves Ducharme, Yves Girard, Chun Li, Annette Robichoud